Rauch, Philipp J. http://orcid.org/0000-0001-8677-0986
Gopakumar, Jayakrishnan http://orcid.org/0000-0003-3895-8188
Silver, Alexander J. http://orcid.org/0000-0001-8255-3140
Nachun, Daniel
Ahmad, Herra http://orcid.org/0000-0003-1871-9614
McConkey, Marie
Nakao, Tetsushi http://orcid.org/0000-0001-9979-2682
Bosse, Marc http://orcid.org/0000-0003-4912-8059
Rentz, Thiago
Vivanco Gonzalez, Nora
Greenwald, Noah F. http://orcid.org/0000-0002-7836-4379
McCaffrey, Erin F.
Khair, Zumana
Gopakumar, Manu
Rodrigues, Kameron B. http://orcid.org/0000-0002-0270-3688
Lin, Amy E.
Sinha, Eti http://orcid.org/0000-0003-4680-0321
Fefer, Maia
Cohen, Drew N.
Vromman, Amélie
Shvartz, Eugenia
Sukhova, Galina
Bendall, Sean
Angelo, Michael http://orcid.org/0000-0003-1531-5067
Libby, Peter http://orcid.org/0000-0002-1502-502X
Ebert, Benjamin L. http://orcid.org/0000-0003-0197-5451
Jaiswal, Siddhartha http://orcid.org/0000-0002-9597-0477
Funding for this research was provided by:
Burroughs Wellcome Fund
EvansMDS Foundation
U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute (R01HL080472, R01HL082945)
Article History
Received: 6 October 2021
Accepted: 27 July 2023
First Online: 4 September 2023
Competing interests
: M.B. is presently a consultant for the company IonPath Inc., which manufactured the MIBI-TOF instrument used in this paper. A.E.L. is a member of TenSixteen Bio, outside of the submitted work. E.M. previously consulted for IonPath Inc. M.A. is a board member and shareholder in IonPath, which develops and manufactures the commercial MIBI-TOF platform. P.L. is an unpaid consultant to, or involved in, clinical trials for Amgen, AstraZeneca, Baim Institute, Beren Therapeutics, Esperion Therapeutics, Genentech, Kancera, Kowa Pharmaceuticals, Medimmune, Merck, Moderna, Novo Nordisk, Novartis, Pfizer and Sanofi-Regeneron. P.L. is a member of the scientific advisory board for Amgen, Caristo Diagnostics, Cartesian Therapeutics, CSL Behring, DalCor Pharmaceuticals, Dewpoint Therapeutics, Eulicid Bioimaging, Kancera, Kowa Pharmaceuticals, Olatec Therapeutics, Medimmune, Novartis, PlaqueTec, TenSixteen Bio, Soley Therapeutics and XBiotech, Inc. P.L.’s laboratory has received research funding in the last 2 years from Novartis, Novo Nordisk and Genentech. P.L. is on the Board of Directors of XBiotech, Inc. and has a financial interest in XBiotech, a company developing therapeutic human antibodies; in TenSixteen Bio, a company targeting somatic mosaicism and CHIP to discover and develop new therapeutics to treat age-related diseases; and in Soley Therapeutics, a biotechnology company that is combining artificial intelligence with molecular and cellular response detection for discovering and developing new drugs, currently focusing on cancer therapeutics. P.L.’s interests were reviewed and are managed by Brigham and Women’s Hospital and Mass General Brigham in accordance with their conflict-of-interest policies. B.L.E. has received consulting fees from GRAIL. He is a member of the scientific advisory board and shareholder for Neomorph Therapeutics, Skyhawk Therapeutics and Exo Therapeutics. B.L.E.’s laboratory has received research funding in the last 2 years from Novartis and Calico. S.J. is a scientific advisor to AstraZeneca, Novartis, Genentech, AVRO Bio and Foresite Labs, reports speaking fees from GSK, is an equity holder and on the scientific advisory board for Bitterroot Bio, and is an equity holder, co-founder and on the scientific advisory board of TenSixteen Bio. The other authors declare no competing interests.